<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: It remains unclear whether primary prophylactic implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) therapy is cost-effective compared with a 'no <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> strategy' in the European health care setting </plain></SENT>
<SENT sid="1" pm="."><plain>We performed a cost-effectiveness analysis for a cohort of patients with a left ventricular ejection fraction &lt;40% and ischaemic or non-<z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischaemic heart disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: A Markov decision analytic model was used to evaluate long-term survival, quality-adjusted life years (QALYs), and lifetime costs for a cohort of patients with a reduced left ventricular function without previous <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, managed with a prophylactic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Input data on effectiveness were derived from a meta-analysis of primary prophylactic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-only therapy randomized trials, from a prospective cohort study of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> patients, from a health care utilization survey, and from the literature </plain></SENT>
<SENT sid="4" pm="."><plain>Input data on costs were derived from a micro-cost analysis </plain></SENT>
<SENT sid="5" pm="."><plain>Data on quality-of-life were derived from the literature </plain></SENT>
<SENT sid="6" pm="."><plain>Deterministic and probabilistic sensitivity analysis was performed to assess the uncertainty </plain></SENT>
<SENT sid="7" pm="."><plain>Probabilistic sensitivity analysis demonstrated a mean lifetime cost of €50 685 ± €4604 and 6.26 ± 0.64 QALYs for patients in the 'no <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> strategy' </plain></SENT>
<SENT sid="8" pm="."><plain>Patients in the '<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> strategy' accumulated €86 759 ± ��3343 and an effectiveness of 7.08 ± 0.71 QALYs yielding an incremental cost-effectiveness ratio of €43 993/QALY gained compared with the 'no <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> strategy' </plain></SENT>
<SENT sid="9" pm="."><plain>The probability that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy is cost-effective was 65% at a willingness-to-pay threshold of €80 000/QALY </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Our results suggest that primary prophylactic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy in patients with a left ventricular ejection fraction &lt;40% and ischaemic or non-<z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischaemic heart disease</z:e> is cost-effective in the European setting </plain></SENT>
</text></document>